{"id":19079,"date":"2024-12-20T17:43:38","date_gmt":"2024-12-20T09:43:38","guid":{"rendered":"https:\/\/flcube.com\/?p=19079"},"modified":"2024-12-20T17:43:40","modified_gmt":"2024-12-20T09:43:40","slug":"wuxi-biologics-enters-licensing-deal-with-hangzhou-dac-and-aadi-bio-for-preclinical-adc-portfolio","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=19079","title":{"rendered":"WuXi Biologics Enters Licensing Deal with Hangzhou DAC and Aadi Bio for Preclinical ADC Portfolio"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">China-based Contract Research and Development Organization (CRDMO) WuXi Biologics (<a href=\"https:\/\/www.google.com\/finance\/quote\/2269:HKG\">HKG: 2269<\/a>) has announced a strategic licensing agreement with compatriot firm Hangzhou DAC Biotechnology Co., Ltd, an antibody drug conjugate (ADC) specialist, and US-based Aadi Bioscience, Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/AADI:NASDAQ\">NASDAQ: AADI<\/a>). The deal grants Aadi Bio global d2018evelopment and commercialization rights to a three-asset portfolio of preclinical ADCs.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Financial Terms of the Licensing Agreement<\/strong><br>Under the terms of the agreement, Aadi will pay an aggregate of USD 44 million upfront for the in-licensing ADC programs. This significant upfront investment underscores the confidence in the potential of the preclinical assets. Furthermore, Aadi is obligated to pay cumulative development milestone payments of up to USD 265 million, cumulative commercial milestone payments of up to USD 540 million, and single-digit royalties on sales, reflecting the long-term commitment and expected commercial success of the ADC portfolio.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Implications for the ADC Landscape and WuXi Biologics&#8217; Strategic Positioning<\/strong><br>This licensing agreement represents a significant step forward for WuXi Biologics in expanding its strategic partnerships and securing a strong position in the ADC landscape. By partnering with both Hangzhou DAC and Aadi Bioscience, WuXi Biologics is set to benefit from the combined expertise and global reach of these companies, potentially leading to innovative treatments and significant advancements in the field of antibody drug conjugates.<a href=\"https:\/\/flcube.com\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China-based Contract Research and Development Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced a strategic&#8230;<\/p>\n","protected":false},"author":1,"featured_media":19082,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[2860,35,2859,952,2861,292],"class_list":["post-19079","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-aadi-bioscience","tag-adc-xdc","tag-dac-biotechnology","tag-hkg-2269","tag-nasdaq-aadi","tag-wuxi-biologics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>WuXi Biologics Enters Licensing Deal with Hangzhou DAC and Aadi Bio for Preclinical ADC Portfolio - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Contract Research and Development Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced a strategic licensing agreement with compatriot firm Hangzhou DAC Biotechnology Co., Ltd, an antibody drug conjugate (ADC) specialist, and US-based Aadi Bioscience, Inc. (NASDAQ: AADI). The deal grants Aadi Bio global development and commercialization rights to a three-asset portfolio of preclinical ADCs.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=19079\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"WuXi Biologics Enters Licensing Deal with Hangzhou DAC and Aadi Bio for Preclinical ADC Portfolio\" \/>\n<meta property=\"og:description\" content=\"China-based Contract Research and Development Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced a strategic licensing agreement with compatriot firm Hangzhou DAC Biotechnology Co., Ltd, an antibody drug conjugate (ADC) specialist, and US-based Aadi Bioscience, Inc. (NASDAQ: AADI). The deal grants Aadi Bio global d2018evelopment and commercialization rights to a three-asset portfolio of preclinical ADCs.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=19079\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-20T09:43:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-20T09:43:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2018.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19079#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19079\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"WuXi Biologics Enters Licensing Deal with Hangzhou DAC and Aadi Bio for Preclinical ADC Portfolio\",\"datePublished\":\"2024-12-20T09:43:38+00:00\",\"dateModified\":\"2024-12-20T09:43:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19079\"},\"wordCount\":230,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19079#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/2018.png\",\"keywords\":[\"Aadi Bioscience\",\"ADC \\\/ XDC\",\"DAC Biotechnology\",\"HKG: 2269\",\"NASDAQ: AADI\",\"WuXi Biologics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=19079#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19079\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=19079\",\"name\":\"WuXi Biologics Enters Licensing Deal with Hangzhou DAC and Aadi Bio for Preclinical ADC Portfolio - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19079#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19079#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/2018.png\",\"datePublished\":\"2024-12-20T09:43:38+00:00\",\"dateModified\":\"2024-12-20T09:43:40+00:00\",\"description\":\"China-based Contract Research and Development Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced a strategic licensing agreement with compatriot firm Hangzhou DAC Biotechnology Co., Ltd, an antibody drug conjugate (ADC) specialist, and US-based Aadi Bioscience, Inc. (NASDAQ: AADI). The deal grants Aadi Bio global development and commercialization rights to a three-asset portfolio of preclinical ADCs.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19079#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=19079\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19079#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/2018.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/2018.png\",\"width\":1080,\"height\":608,\"caption\":\"WuXi Biologics Enters Licensing Deal with Hangzhou DAC and Aadi Bio for Preclinical ADC Portfolio\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19079#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"WuXi Biologics Enters Licensing Deal with Hangzhou DAC and Aadi Bio for Preclinical ADC Portfolio\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"WuXi Biologics Enters Licensing Deal with Hangzhou DAC and Aadi Bio for Preclinical ADC Portfolio - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Contract Research and Development Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced a strategic licensing agreement with compatriot firm Hangzhou DAC Biotechnology Co., Ltd, an antibody drug conjugate (ADC) specialist, and US-based Aadi Bioscience, Inc. (NASDAQ: AADI). The deal grants Aadi Bio global development and commercialization rights to a three-asset portfolio of preclinical ADCs.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=19079","og_locale":"en_US","og_type":"article","og_title":"WuXi Biologics Enters Licensing Deal with Hangzhou DAC and Aadi Bio for Preclinical ADC Portfolio","og_description":"China-based Contract Research and Development Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced a strategic licensing agreement with compatriot firm Hangzhou DAC Biotechnology Co., Ltd, an antibody drug conjugate (ADC) specialist, and US-based Aadi Bioscience, Inc. (NASDAQ: AADI). The deal grants Aadi Bio global d2018evelopment and commercialization rights to a three-asset portfolio of preclinical ADCs.","og_url":"https:\/\/flcube.com\/?p=19079","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-12-20T09:43:38+00:00","article_modified_time":"2024-12-20T09:43:40+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2018.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=19079#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=19079"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"WuXi Biologics Enters Licensing Deal with Hangzhou DAC and Aadi Bio for Preclinical ADC Portfolio","datePublished":"2024-12-20T09:43:38+00:00","dateModified":"2024-12-20T09:43:40+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=19079"},"wordCount":230,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=19079#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2018.png","keywords":["Aadi Bioscience","ADC \/ XDC","DAC Biotechnology","HKG: 2269","NASDAQ: AADI","WuXi Biologics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=19079#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=19079","url":"https:\/\/flcube.com\/?p=19079","name":"WuXi Biologics Enters Licensing Deal with Hangzhou DAC and Aadi Bio for Preclinical ADC Portfolio - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=19079#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=19079#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2018.png","datePublished":"2024-12-20T09:43:38+00:00","dateModified":"2024-12-20T09:43:40+00:00","description":"China-based Contract Research and Development Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced a strategic licensing agreement with compatriot firm Hangzhou DAC Biotechnology Co., Ltd, an antibody drug conjugate (ADC) specialist, and US-based Aadi Bioscience, Inc. (NASDAQ: AADI). The deal grants Aadi Bio global development and commercialization rights to a three-asset portfolio of preclinical ADCs.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=19079#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=19079"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=19079#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2018.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2018.png","width":1080,"height":608,"caption":"WuXi Biologics Enters Licensing Deal with Hangzhou DAC and Aadi Bio for Preclinical ADC Portfolio"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=19079#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"WuXi Biologics Enters Licensing Deal with Hangzhou DAC and Aadi Bio for Preclinical ADC Portfolio"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2018.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19079","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=19079"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19079\/revisions"}],"predecessor-version":[{"id":19083,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19079\/revisions\/19083"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/19082"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=19079"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=19079"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=19079"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}